The DOI matches its Crossref record; 95 of the 95 references it cites were found in a registry or an index.
Lung Cancer Biomarkers
Open accessAbstract
Synopsis The molecular characterization of lung cancer has considerably changed the classification and treatment of these tumors, becoming an essential component of pathologic diagnosis and oncologic therapy decisions. Through the recognition of novel biomarkers, such as epidermal growth factor receptor mutations and anaplastic lymphoma kinase translocations, it has been possible to identify subsets of patients who benefit from targeted molecular therapies. The success of targeted anticancer therapies and new immunotherapy approaches has created a new paradigm of personalized therapy and has also led to accelerated development of new drugs for lung cancer treatment. This review focuses on clinically relevant cancer biomarkers as targets for therapy, as well as potential new targets for drug development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Siegel, R., Naishadham, D., & Jemal, A. (2013) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21166 · Cited by 11,825
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198
First-Line Crizotinib versus Chemotherapy in ALK -Positive Lung Cancer
Solomon, B. J., Mok, T., Kim, D.-W., Wu, Y.-L., Nakagawa, K., Mekhail, T., Felip, E., Cappuzzo, F., Paolini, J., Usari, T., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408440 · Cited by 3,190
Epidermal growth factor receptor mutations in lung cancer
Sharma, S. V., Bell, D. W., Settleman, J., & Haber, D. A. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2088 · Cited by 3,170
Somatic mutations affect key pathways in lung adenocarcinoma
Ding, L., Getz, G., Wheeler, D. A., Mardis, E. R., McLellan, M. D., Cibulskis, K., Sougnez, C., Greulich, H., Muzny, D. M., Morgan, M. B., et al. (2008) · Nature · doi:10.1038/nature07423 · Cited by 2,681
Self-citationTaube, J. M., Anders, R. A., Young, G. D., Xu, H., Sharma, R., McMiller, T. L., Chen, S., Klein, A. P., Pardoll, D. M., Topalian, S. L., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003689 · Cited by 2,157
Travis, W. D., Brambilla, E., Burke, A. P., Marx, A., & Nicholson, A. G. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000663 · Cited by 1,905
Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations
Hyman, D. M., Puzanov, I., Subbiah, V., Faris, J. E., Chau, I., Blay, J.-Y., Wolf, J., Raje, N. S., Diamond, E. L., Hollebecque, A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1502309 · Cited by 1,764 · cited 1×
“BRAF inhibitors, such as vemurafenib and dabrafenib, have high and selective activity against the V600E-mutant BRAF kinase, with overall responses rates from 33% to 42%.(63,64) BRAF and MEK inhibitors targeting BRAF mutation–positive NSCLC, such as”
BackgroundROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers
Bergethon, K., Shaw, A. T., Ignatius Ou, S.-H., Katayama, R., Lovly, C. M., McDonald, N. T., Massion, P. P., Siwak-Tapp, C., Gonzalez, A., Fang, R., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.6345 · Cited by 1,555
Schmidt, L., Duh, F.-M., Chen, F., Kishida, T., Glenn, G., Choyke, P., Scherer, S. W., Zhuang, Z., Lubensky, I., Dean, M., et al. (1997) · Nature Genetics · doi:10.1038/ng0597-68 · Cited by 1,524
KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib
Pao, W., Wang, T. Y., Riely, G. J., Miller, V. A., Pan, Q., Ladanyi, M., Zakowski, M. F., Heelan, R. T., Kris, M. G., & Varmus, H. E. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020017 · Cited by 1,516
EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors
Choi, Y. L., Soda, M., Yamashita, Y., Ueno, T., Takashima, J., Nakajima, T., Yatabe, Y., Takeuchi, K., Hamada, T., Haruta, H., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1007478 · Cited by 1,189
Gettinger, S. N., Horn, L., Gandhi, L., Spigel, D. R., Antonia, S. J., Rizvi, N. A., Powderly, J. D., Heist, R. S., Carvajal, R. D., Jackman, D. M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.3708 · Cited by 1,177
Lynch, T. J., Bondarenko, I., Luft, A., Serwatowski, P., Barlesi, F., Chacko, R., Sebastian, M., Neal, J., Lu, H., Cuillerot, J.-M., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.4032 · Cited by 1,002
Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies
Lipson, D., Capelletti, M., Yelensky, R., Otto, G., Parker, A., Jarosz, M., Curran, J. A., Balasubramanian, S., Bloom, T., Brennan, K. W., et al. (2012) · Nature Medicine · doi:10.1038/nm.2673 · Cited by 869
Weiss, J., Sos, M. L., Seidel, D., Peifer, M., Zander, T., Heuckmann, J. M., Ullrich, R. T., Menon, R., Maier, S., Soltermann, A., et al. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3001451 · Cited by 821
Garnett, M. J., & Marais, R. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.09.022 · Cited by 799
Programmed death ligand-1 expression in non-small cell lung cancer
Velcheti, V., Schalper, K. A., Carvajal, D. E., Anagnostou, V. K., Syrigos, K. N., Sznol, M., Herbst, R. S., Gettinger, S. N., Chen, L., & Rimm, D. L. (2014) · Laboratory Investigation · doi:10.1038/labinvest.2013.130 · Cited by 755
Clinical Characteristics of Patients With Lung Adenocarcinomas Harboring BRAF Mutations
Paik, P. K., Arcila, M. E., Fara, M., Sima, C. S., Miller, V. A., Kris, M. G., Ladanyi, M., & Riely, G. J. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.1280 · Cited by 691
Somatic Mutations of the HER2 Kinase Domain in Lung Adenocarcinomas
Shigematsu, H., Takahashi, T., Nomura, M., Majmudar, K., Suzuki, M., Lee, H., Wistuba, I. I., Fong, K. M., Toyooka, S., Shimizu, N., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4235 · Cited by 678
Self-citationMazières, J., Peters, S., Lepage, B., Cortot, A. B., Barlesi, F., Beau-Faller, M., Besse, B., Blons, H., Mansuet-Lupo, A., Urban, T., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.6095 · Cited by 668
Jänne, P. A., Shaw, A. T., Pereira, J. R., Jeannin, G., Vansteenkiste, J., Barrios, C., Franke, F. A., Grinsted, L., Zazulina, V., Smith, P., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70489-8 · Cited by 655
Dogan, S., Shen, R., Ang, D. C., Johnson, M. L., D'Angelo, S. P., Paik, P. K., Brzostowski, E. B., Riely, G. J., Kris, M. G., Zakowski, M. F., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-3265 · Cited by 639
Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer
Vaishnavi, A., Capelletti, M., Le, A. T., Kako, S., Butaney, M., Ercan, D., Mahale, S., Davies, K. D., Aisner, D. L., Pilling, A. B., et al. (2013) · Nature Medicine · doi:10.1038/nm.3352 · Cited by 607
New Pathologic Classification of Lung Cancer: Relevance for Clinical Practice and Clinical Trials
Travis, W. D., Brambilla, E., & Riely, G. J. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.9270 · Cited by 599
Paik, P. K., Drilon, A., Fan, P.-D., Yu, H., Rekhtman, N., Ginsberg, M. S., Borsu, L., Schultz, N., Berger, M. F., Rudin, C. M., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-1467 · Cited by 575
RET Fusions Define a Unique Molecular and Clinicopathologic Subtype of Non–Small-Cell Lung Cancer
Wang, R., Hu, H., Pan, Y., Li, Y., Ye, T., Li, C., Luo, X., Wang, L., Li, H., Zhang, Y., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.1477 · Cited by 546
Oncogenic Mutations of PIK3CA in Human Cancers
Samuels, Y., & Velculescu, V. E. (2004) · Cell Cycle · doi:10.4161/cc.3.10.1164 · Cited by 538
Mutation of the PIK3CA oncogene in human cancers
Karakas, B., Bachman, K. E., & Park, B. H. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6602970 · Cited by 505
Mutations in the DDR2 Kinase Gene Identify a Novel Therapeutic Target in Squamous Cell Lung Cancer
Hammerman, P. S., Sos, M. L., Ramos, A. H., Xu, C., Dutt, A., Zhou, W., Brace, L. E., Woods, B. A., Lin, W., Zhang, J., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8274.cd-11-0005 · Cited by 482
Response to Cabozantinib in Patients with RET Fusion-Positive Lung Adenocarcinomas
Drilon, A., Wang, L., Hasanovic, A., Suehara, Y., Lipson, D., Stephens, P., Ross, J., Miller, V., Ginsberg, M., Zakowski, M. F., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0035 · Cited by 464
Planchard, D., Kim, T. M., Mazieres, J., Quoix, E., Riely, G., Barlesi, F., Souquet, P.-J., Smit, E. F., Groen, H. J. M., Kelly, R. J., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)00077-2 · Cited by 453
Sholl, L. M., Aisner, D. L., Varella-Garcia, M., Berry, L. D., Dias-Santagata, D., Wistuba, I. I., Chen, H., Fujimoto, J., Kugler, K., Franklin, W. A., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000516 · Cited by 430
Self-citationPIK3CA Mutations and Copy Number Gains in Human Lung Cancers
Yamamoto, H., Shigematsu, H., Nomura, M., Lockwood, W. W., Sato, M., Okumura, N., Soh, J., Suzuki, M., Wistuba, I. I., Fong, K. M., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5084 · Cited by 429
Self-citationCardarella, S., Ogino, A., Nishino, M., Butaney, M., Shen, J., Lydon, C., Yeap, B. Y., Sholl, L. M., Johnson, B. E., & Jänne, P. A. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0657 · Cited by 372
Mazières, J., Zalcman, G., Crinò, L., Biondani, P., Barlesi, F., Filleron, T., Dingemans, A.-M. C., Léna, H., Monnet, I., Rothschild, S. I., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.3302 · Cited by 369
Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors
Dienstmann, R., Rodon, J., Prat, A., Perez-Garcia, J., Adamo, B., Felip, E., Cortes, J., Iafrate, A. J., Nuciforo, P., & Tabernero, J. (2014) · Annals of Oncology · doi:10.1093/annonc/mdt419 · Cited by 365
Blumenschein, G. R., Smit, E. F., Planchard, D., Kim, D.-W., Cadranel, J., De Pas, T., Dunphy, F., Udud, K., Ahn, M.-J., Hanna, N. H., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv072 · Cited by 349
Sasaki, T., Okuda, K., Zheng, W., Butrynski, J., Capelletti, M., Wang, L., Gray, N. S., Wilner, K., Christensen, J. G., Demetri, G., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-2956 · Cited by 335
Gozgit, J. M., Wong, M. J., Moran, L., Wardwell, S., Mohemmad, Q. K., Narasimhan, N. I., Shakespeare, W. C., Wang, F., Clackson, T., & Rivera, V. M. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0450 · Cited by 320
Structure and Chemical Inhibition of the RET Tyrosine Kinase Domain
Knowles, P. P., Murray-Rust, J., Kjær, S., Scott, R. P., Hanrahan, S., Santoro, M., Ibáñez, C. F., & McDonald, N. Q. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m605604200 · Cited by 302
Kerr, K. M., Bubendorf, L., Edelman, M. J., Marchetti, A., Mok, T., Novello, S., O'Byrne, K., Stahel, R., Peters, S., Felip, E., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu145 · Cited by 298
Shepherd, F. A., Domerg, C., Hainaut, P., Jänne, P. A., Pignon, J.-P., Graziano, S., Douillard, J.-Y., Brambilla, E., Le Chevalier, T., Seymour, L., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.48.1390 · Cited by 293
Paik, J. H., Choe, G., Kim, H., Choe, J.-Y., Lee, H. J., Lee, C.-T., Lee, J. S., Jheon, S., & Chung, J.-H. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31820b82e8 · Cited by 277
PIK3CA mutation status in Japanese lung cancer patients
Kawano, O., Sasaki, H., Endo, K., Suzuki, E., Haneda, H., Yukiue, H., Kobayashi, Y., Yano, M., & Fujii, Y. (2006) · Lung Cancer · doi:10.1016/j.lungcan.2006.07.006 · Cited by 273
Yi, E. S., Boland, J. M., Maleszewski, J. J., Roden, A. C., Oliveira, A. M., Aubry, M.-C., Erickson-Johnson, M. R., Caron, B. L., Li, Y., Tang, H., et al. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318209edb9 · Cited by 263
Recurrent KRAS codon 146 mutations in human colorectal cancer
Edkins, S., & O’Meara, S. (2006) · Cancer Biology & Therapy · doi:10.4161/cbt.5.8.3251 · Cited by 229
Beau-Faller, M., Ruppert, A.-M., Voegeli, A.-C., Neuville, A., Meyer, N., Guerin, E., Legrain, M., Mennecier, B., Wihlm, J.-M., Massard, G., et al. (2008) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318168d9d4 · Cited by 201
An, S.-J., Chen, Z.-H., Su, J., Zhang, X.-C., Zhong, W.-Z., Yang, J.-J., Zhou, Q., Yang, X.-N., Huang, L., Guan, J.-L., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0040109 · Cited by 176
Inhibitor-Sensitive FGFR2 and FGFR3 Mutations in Lung Squamous Cell Carcinoma
Liao, R. G., Jung, J., Tchaicha, J., Wilkerson, M. D., Sivachenko, A., Beauchamp, E. M., Liu, Q., Pugh, T. J., Pedamallu, C. S., Hayes, D. N., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3950 · Cited by 167
ROS1-Rearranged Lung Cancer: A Clinicopathologic and Molecular Study of 15 Surgical Cases
Yoshida, A., Kohno, T., Tsuta, K., Wakai, S., Arai, Y., Shimada, Y., Asamura, H., Furuta, K., Shibata, T., & Tsuda, H. (2013) · American Journal of Surgical Pathology · doi:10.1097/pas.0b013e3182758fe6 · Cited by 165
Sholl, L. M., Weremowicz, S., Gray, S. W., Wong, K.-K., Chirieac, L. R., Lindeman, N. I., & Hornick, J. L. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31827db604 · Cited by 162
Lung Cancer Biomarkers: Present Status and Future Developments
Cagle, P. T., Allen, T. C., & Olsen, R. J. (2013) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2013-0319-cr · Cited by 162
Personalized medicine in lung cancer: what we need to know
Mok, T. S. K. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.126 · Cited by 158
Sun, J., Zhou, W., Choi, Y., Choi, S., Kim, S. E., Wang, Z., Dolled-Filhart, M. P., Emancipator, K., Wu, D., WEINER, R. S., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.04.007 · Cited by 153
Cabillic, F., Gros, A., Dugay, F., Bégueret, H., Mesturoux, L., Chiforeanu, D. C., Dufrenot-Petitjean-Roget, L., Jauffret, V., Dachary, D., Corre, R., et al. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000072 · Cited by 151
Pekar‐Zlotin, M., Hirsch, F. R., Soussan‐Gutman, L., Ilouze, M., Dvir, A., Boyle, T. A., Wynes, M. W., Miller, V. A., Lipson, D., Palmer, G. A., et al. (2015) · The Oncologist · doi:10.1634/theoncologist.2014-0389 · Cited by 151
RET and NTRK1 proto‐oncogenes in human diseases
Alberti, L., Carniti, C., Miranda, C., Roccato, E., & Pierotti, M. A. (2003) · Journal of Cellular Physiology · doi:10.1002/jcp.10252 · Cited by 147
Masuya, D., Huang, C., Liu, D., Nakashima, T., Kameyama, K., Haba, R., Ueno, M., & Yokomise, H. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601718 · Cited by 141
ALK inhibitors in non-small cell lung cancer: the latest evidence and developments
Sullivan, I., & Planchard, D. (2015) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834015617355 · Cited by 140
Wallander, M. L., Geiersbach, K. B., Tripp, S. R., & Layfield, L. J. (2012) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2011-0321-oa · Cited by 115
HIP1–ALK, A Novel ALK Fusion Variant that Responds to Crizotinib
Fang, D. D., Zhang, B., Gu, Q., Lira, M. E., Xu, Q., Sun, H., Qian, M., Sheng, W., Ozeck, M., Wang, Z., et al. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000087 · Cited by 95
Regional chromosomal localization of N-ras, K-ras-1, K-ras-2 andmyboncogenes in human cells
McBride, O. W., Swan, D. C., Tronick, S. R., Gol, R., Klimanis, D., Moore, D. E., & Aaronson, S. A. (1983) · Nucleic Acids Research · doi:10.1093/nar/11.23.8221 · Cited by 93
Sorensen, S. F., Zhou, W., Dolled-Filhart, M. P., Georgsen, J. B., Wang, Z., Emancipator, K., Wu, D., Busch-Sørensen, M., Meldgaard, P., & Hager, H. (2016) · Translational Oncology · doi:10.1016/j.tranon.2016.01.003 · Cited by 88
KRASoncogene in lung cancer: focus on molecularly driven clinical trials
Kempf, E., Rousseau, B., Besse, B., & Paz-Ares, L. G. (2016) · European Respiratory Review · doi:10.1183/16000617.0071-2015 · Cited by 85
Endoh, H., Yatabe, Y., Kosaka, T., Kuwano, H., & Mitsudomi, T. (2006) · Journal of Thoracic Oncology · doi:10.1016/s1556-0864(15)30374-9 · Cited by 82
NSCLC and HER2: between lights and shadows
Ricciardi, G. R. R., Russo, A., Franchina, T., Ferraro, G., Zanghì, M., Picone, A., Scimone, A., & Adamo, V. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000379 · Cited by 78
Dingemans, A. C., Mellema, W. W., Groen, H. J. M., van Wijk, A. W., Burgers, S. A., Kunst, P. W. A., Thunnissen, E., Heideman, D. A. M., & Smit, E. F. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1779 · Cited by 78
Biomarkers in Lung Adenocarcinoma: A Decade of Progress
Sholl, L. M. (2014) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2014-0128-ra · Cited by 76
Martínez, P., Hernández‐Losa, J., Montero, M. Á., Cedrés, S., Castellví, J., Martínez‐Martí, A., Tallada, N., Murtra-Garrell, N., Navarro-Mendivill, A., Rodríguez-Freixinós, V., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0052261 · Cited by 73
FGFR as potential target in the treatment of squamous non small cell lung cancer
Tiseo, M., Gelsomino, F., Alfieri, R. R., Cavazzoni, A., Bozzetti, C., Giorgi, A. D., Petronini, P. G., & Ardizzoni, A. (2015) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2015.04.011 · Cited by 69
From targets to targeted therapies and molecular profiling in non-small cell lung carcinoma
Thomas, A., Rajan, A., López-Chávez, A., Wang, Y., & Giaccone, G. (2012) · Annals of Oncology · doi:10.1093/annonc/mds478 · Cited by 64
Beauchamp, E. M., Woods, B. A., Dulak, A. M., Tan, L., Xu, C., Gray, N. S., Bass, A. J., Wong, K., Meyerson, M. M., & Hammerman, P. S. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0817 · Cited by 63
Current concepts on the molecular pathology of non-small cell lung carcinoma
Fujimoto, J., & Wistuba, I. I. (2014) · Seminars in Diagnostic Pathology · doi:10.1053/j.semdp.2014.06.008 · Cited by 58
Self-citationDiscoidin Domain Receptor 2 Signaling Networks and Therapy in Lung Cancer
Payne, L. S., & Huang, P. H. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000164 · Cited by 54
Does KRAS mutational status predict chemoresistance in advanced non-small cell lung cancer (NSCLC)?
Macerelli, M., Caramella, C., Faivre, L., Besse, B., Planchard, D., Polo, V., Camus, M. N., Celebic, A., Koubi-Pick, V., Lacroix, L., et al. (2014) · Lung Cancer · doi:10.1016/j.lungcan.2013.12.013 · Cited by 52
Anaplastic lymphoma kinase: Role in cancer and therapy perspective
Zhao, Z., Verma, V., & Zhang, M. (2015) · Cancer Biology & Therapy · doi:10.1080/15384047.2015.1095407 · Cited by 50
Immune Checkpoint Blockade: The Hope for Immunotherapy as a Treatment of Lung Cancer?
Brahmer, J. R. (2013) · Seminars in Oncology · doi:10.1053/j.seminoncol.2013.12.014 · Cited by 49
Cao, B., Wei, P., Liu, Z., Bi, R., Lu, Y., Zhang, L., Zhang, J., Yang, Y., Shen, C., Du, X., et al. (2015) · OncoTargets and Therapy · doi:10.2147/ott.s94997 · Cited by 47
New strategies in immunotherapy for non-small cell lung cancer.
Carrizosa, D. R., & Gold, K. A. (2015) · PubMed · doi:10.3978/j.issn.2218-6751.2015.06.05 · Cited by 46
Comprehensive Molecular Analysis of NSCLC; Clinicopathological Associations
Chatziandreou, I., Tsioli, P., Sakellariou, S., Mourkioti, I., Giannopoulou, I., Levidou, G., Korkolopoulou, P. A., Patsouris, E., & Saetta, A. A. (2015) · PLoS ONE · doi:10.1371/journal.pone.0133859 · Cited by 43
Clinicopathologic Characteristics of Patients with HER2 Insertions in Non-small Cell Lung Cancer
Bu, S., Wang, R., Pan, Y., Yu, S. J., Shen, X., Li, Y., Sun, Y., & Chen, H. (2016) · Annals of Surgical Oncology · doi:10.1245/s10434-015-5044-8 · Cited by 37
Immune Checkpoint Inhibitors in Lung Cancer: Past, Present and Future
Seetharamu, N., Budman, D. R., & Sullivan, K. M. (2016) · Future Oncology · doi:10.2217/fon.16.20 · Cited by 35
Chen, J., Cheng, Y., Han, L., Wei, F., Yu, W., Zhang, X., Cao, S., & Yu, J. (2015) · PubMed Central · doi:10.7497/j.issn.2095-3941.2015.0021 · Cited by 32
Advances in EGFR as a Predictive Marker in Lung Adenocarcinoma
Khalil, F. K., & Altiok, S. (2015) · Cancer Control · doi:10.1177/107327481502200210 · Cited by 31
The potential of neurotrophic tyrosine kinase (NTRK) inhibitors for treating lung cancer
Passiglia, F., Caparica, R., Giovannetti, E., Giallombardo, M., Listì, A., Diana, P., Cirrincione, G., Caglevic, C., Raez, L. E., Russo, A. D., et al. (2016) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2016.1152261 · Cited by 30
Fan, X., Liu, B., Xu, H., Yu, B., Shi, S., Zhang, J., Wang, X., Wang, J., Lu, Z., Ma, H., et al. (2013) · Human Pathology · doi:10.1016/j.humpath.2012.12.002 · Cited by 28
Anaplastic lymphoma kinase rearrangement in lung Cancer: Its biological and clinical significance
Toyokawa, G., & Seto, T. (2014) · Respiratory Investigation · doi:10.1016/j.resinv.2014.06.005 · Cited by 24
Ying, M., Zhu, X., Yang, Z., Li, D.-H., & Chen, L. (2015) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2015.16.10.4439 · Cited by 23
Immune checkpoint‑targeted cancer immunotherapies
Swatler, J., & Kozłowska, E. (2016) · Postępy Higieny i Medycyny Doświadczalnej · doi:10.5604/17322693.1192926 · Cited by 19
Cited by
Pyroptosis: Mechanisms and Diseases
Yu, P., Zhang, X., Liu, N., Tang, L., Peng, C., & Chen, X. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00507-5 · Cited by 2,353
Melosky, B., Kambartel, K., Häntschel, M., Bennetts, M., Nickens, D. J., Brinkmann, J., Kayser, A., Moran, M., & Cappuzzo, F. (2022) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-021-00563-1 · Cited by 255
Metadata
- Authors
- Villalobos, P., & Wistuba, I. I.
- Venue
- Hematology/Oncology Clinics of North America
- Publisher
- Elsevier BV
- Published
- 2017-02
- Volume
- 31
- Issue
- 1
- Pages
- 13-29
- ISSN
- 0889-8588 (ISSN-L)
- OpenAlex
- W3021050361
- Cited by
- 254
- References
- 95
- FWCI
- 7.94
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.